Items tagged with Vaccines
Virtual Global Forum on TB Vaccines (post)
The Virtual Global Forum on TB Vaccines will be held on 20-22 April 2021 and will review the state of the field and recent progress in TB vaccine research and development against the backdrop of the COVID-19 pandemic.
Valo Therapeutics acquires University of Helsinki’s PeptiBAC cancer and infectious disease vaccination technology (post)
Helsinki, Finland, 19 April 2021: Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights for the proprietary ‘PeptiBAC’ technology from the University of Helsinki, Finland.
New support tools for TB vaccine R&D published (post)
The Tuberculosis Vaccine Initiative (TBVI) and the European & Developing Countries Clinical Trials Partnership (EDCTP) developed several new tools to support future TB vaccine clinical trials: templates and guidelines to support preparations for a regulatory plan, a data management plan and clinical trial protocol synopses, and a comprehensive registry of trial sites in sub-Saharan Africa.
Updated TB Vaccine Development Pathway (post)
The Tuberculosis Vaccine Initiative (TBVI) and the International AIDS Vaccine Initiative (IAVI) have updated the TB Vaccine Development Pathway.
TB: The forgotten pandemic (post)
July marks the 100-year anniversary of the Bacille Calmette-Guérin vaccine (BCG), still the only approved vaccine against TB. More than a dozen vaccines for TB are currently being tested in clinical trials: some use whole bacteria as BCG does, while others deliver protein subunits or genetic material carried by viral vectors.
Spanish pharmaceutical company Zendal and IAVI partner to advance the TB vaccine candidate MTBVAC into efficacy trials (post)
-- TB kills 1.4 million people a year, an infectious disease toll only recently surpassed by COVID-19.
-- COVID-19 has reversed years of progress in TB response, costing additional lives and adding to the urgency of the global TB problem.
-- MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.
100 years of a TB vaccine with limited benefit (post)
On July 18, 1921, a newborn child in Paris became the first person to receive an experimental dose of the Bacille Calmette-Guérin vaccine for tuberculosis. A century later, it’s now the most commonly used vaccine in the world. It is also still the only licensed vaccine for the disease.
TB prevention has relied on the same vaccine for 100 years. It’s time for innovation (post)
TB is one of the oldest infectious diseases in recorded history. Most of the people who are ill with TB live in low- and middle-income countries where this disease is one of the leading causes of death. This is particularly distressing given the fact that TB is preventable, treatable and curable. But there’s currently only one vaccine approved against TB. And it is 100 years old. The first dose of the Bacille Calmette-Guérin (BCG) vaccine was administered on July 18 1921. The Conversation Africa’s Ina Skosana poses key questions to Bavesh Kana, one of South Africa’s leading TB researchers.
COVID-19 vaccine pioneer BioNTech plans to make new malaria and TB shots in Africa (post)
BioNTech SE said it would invest some of the profits from the Covid-19 vaccine it markets with Pfizer Inc. into developing shots for malaria and tuberculosis in Africa, part of the German company’s plan to establish a large production hub for innovative medicines on the continent.
Researchers develop novel strategy for TB vaccine (post)
WEST LAFAYETTE, Ind. and HOUSTON, August 20, 2021 – Innovators at Purdue University and Houston Methodist Research Institute have created a novel strategy for developing an effective vaccine for a widespread form of tuberculosis.
Page 17 of 32 · Total posts: 0
←First 16 17 18 Last→